Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3377MR)

This product GTTS-WQ3377MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam CD52 gene. The antibody can be applied in Canine T-cell lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001003240.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403918
UniProt ID Q28896
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3377MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6384MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ7969MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ670MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ14938MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ5144MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ10307MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ2801MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ3366MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW